Anebulo reports positive interim Phase 2 data for ANEB-001 in acute cannabinoid intoxication

Anebulo Pharmaceuticals, Inc.

Part B: 21mg THC challenge; 10mg or 30mg ANEB-001 significantly reduced VAS feeling high (p<0.001), improved alertness (p<0.01), and reduced body sway (p<0.01) vs placebo.
Placebo group: 100% of subjects met VAS threshold for feeling high; only 1 subject per active dose group met threshold.
Safety: adverse events mild/transient except two moderate dizziness cases in Cohort 1 likely THC-attributable.
Company continuing Part B, enrolling third cohort; collaborating with FDA MIDD group on PK/PD model to optimize dosing for ACI.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.